Abivax SA

ABVX · NASDAQ

ABVX is a readout-gated biotech with positive Phase 3 induction data, a much stronger cash position after the 2025 offering, and one big unresolved question: can obefazimod's maintenance data turn runway into a real ulcerative-colitis franchise?

Follow Add to Watchlist Ask Question

NASDAQ ABVX Coverage Bootstrap Biotechnology Ulcerative Colitis Inflammatory Bowel Disease

Latest ReportMay 13, 2026Abivax (ABVX): the ulcerative-colitis readout that has to carry a EUR 530M runwayView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.